ArticleInfectious diseases in clinical practice (Baltimore, Md.)2016
Diagnosis and Treatment of
Article in Infectious diseases in clinical practice (Baltimore, Md.), 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 29 citations in OpenAlex.
- Gut Microbiota-Gut Metabolites andMetabolites · 2024Review
- Gut microbiota and microbiota-based therapies forFrontiers in medicine · 2022Review
- Rapid-format recombinant antibody-based methods for the diagnosis ofFrontiers in microbiology · 2022Review
- Decreasing ICU-associatedBMJ open · 2021Article
- Laboratory markers predictive of fulminantInfection prevention in practice · 2021Article
- Antibiotic Resistances and Molecular Characteristics ofFrontiers in medicine · 2021Article
- GABAergic but not Antidepressant Medications Increase Risk forOpen forum infectious diseases · 2020Article
- Update in Infectious Diseases 2019.Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia · 2019Article
- Doctor, my patient has CDI and should continue to receive antibiotics. The (unresolved) risk of recurrent CDI.Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia · 2019Review
- Advances in the diagnosis and treatment of Clostridium difficile infections.Emerging microbes & infections · 2018Review
- Review
- Evaluation of Copan FecalSwab as Specimen Type for Use in Xpert C. difficile Assay.Journal of clinical microbiology · 2017Article
- Update on Antimicrobial Resistance in Clostridium difficile: Resistance Mechanisms and Antimicrobial Susceptibility Testing.Journal of clinical microbiology · 2017Review
- Assessing the effect of patient screening and isolation on curtailing Clostridium difficile infection in hospital settings.BMC infectious diseases · 2017Article
- Making life difficult for Clostridium difficile: augmenting the pathogen's metabolic model with transcriptomic and codon usage data for better therapeutic target characterization.BMC systems biology · 2017Article
- Antibiotic Resistance and Toxin Production ofFrontiers in microbiology · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 1 country.
Funding
Abstract
Early and accurate diagnosis is essential for optimal treatment of individuals with
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.